Skip to Content

Praxis Precision Medicines, Inc.

Securities Class Action

  • Date:
  • 8/22/2025
  • Company Name:
  • Praxis Precision Medicines, Inc.
  • Stock Symbol:
  • PRAX
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ:PRAX) on behalf of Praxis stockholders. Our investigation concerns whether Praxis has violated the federal securities laws and/or engaged in other unlawful business practices.

On August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025.  Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine.  The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study.

On this news, Praxis's stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025.
If you purchased or otherwise acquired Praxis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Praxis Precision Medicines. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: